← Back to Clinical Trials
Recruiting NCT06006819

Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease

Trial Parameters

Condition Chronic Kidney Diseases
Sponsor Cheng-Hsin General Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 155
Sex ALL
Min Age 20 Years
Max Age 90 Years
Start Date 2023-01-01
Completion 2025-12-23

Brief Summary

Acute heart failure (AHF) is defined as new or worsening of symptoms and signs of heart failure and is the most frequent cause of unplanned hospital admission in elderly patients. N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is one of the most developed prognostic markers for AHR patients and. NT-pro-BNP has limitations in terms of diagnostic or predictive accuracy in patients with chronic kidney disease (CKD). Plasma proteomics have the potential to examine underlying pathophysiological and prognostic roles, so we compared the plasma proteomic signature to predict outcomes of patients with or without CKD hospitalized for AHF.

Eligibility Criteria

Inclusion Criteria: * hospitalized for acute heart failure Exclusion Criteria: * initial serum NT-proBNP level \<300ng/ml, pregnancy, amputated, and end-stage renal disease under regular dialysis

Related Trials